VIR - Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity
Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity
If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underfollowed investment opportunity. This is due to multiple reasons including no bells/whistles of a marketed IPO roadshow, no investment banks starting research coverage helping raise companies' profiles and increasing trading liquidity, a perceived view that a company must have weak business prospects if it goes down the reverse merger path, and an